Physician profile
Marc Dinga
NPI 1760470751
$1,621.12
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $879 · 2020: $633 · 2021: $109.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $514.49 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $385.69 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $158.67 | 2019-2021 | |
| Genzyme Corporation | $122.07 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $84.92 | 2019-2020 | |
| Genentech USA, INC. | $60.61 | 2019 | |
| Mylan Specialty L.P. | $60.20 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $58.16 | 2020 | |
| Sunovion Pharmaceuticals INC. | $47.97 | 2019 | |
| Novartis Pharmaceuticals Corporation | $45.94 | 2019 | |
| Shire North American Group INC | $34.61 | 2019 | |
| Csl Behring | $27.30 | 2020 | |
| Philips North America LLC | $13.49 | 2020 | |
| Sanofi-Aventis U.S. LLC | $7.00 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Dinga listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.